论文部分内容阅读
目的观察金水宝胶囊治疗急性发作期慢性阻塞性肺疾病的临床疗效。方法选取2013年4月—2014年4月惠州市博罗县中医医院收治的急性发作期慢性阻塞性肺疾病患者80例,随机分为观察组与对照组,各40例。对照组患者予以西医常规治疗,观察组患者在对照组基础上加用金水宝胶囊治疗。观察两组患者临床疗效及肺功能各项指标,即第1秒用力呼气容积占预计值百分比(FEV1%)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05);治疗前两组患者FEV1%、FEV1、FEV1/FVC比较,差异无统计学意义(P>0.05);治疗后观察组患者FEV1%、FEV1、FEV1/FVC均高于对照组(P<0.05)。结论金水宝胶囊治疗急性发作期慢性阻塞性肺疾病的临床疗效显著,可提高患者肺功能。
Objective To observe the clinical efficacy of Jinshuibao capsule in the treatment of chronic obstructive pulmonary disease in acute attack. Methods Eighty patients with acute exacerbation of chronic obstructive pulmonary disease admitted from Boluo Hospital of Traditional Chinese Medicine, Huizhou City from April 2013 to April 2014 were randomly divided into observation group and control group, 40 cases in each group. Patients in the control group were given conventional western medicine. Patients in the observation group were treated with Jinshuibao capsules on the basis of the control group. The clinical curative effect and indexes of pulmonary function were observed in two groups of patients, that is, forced expiratory volume in 1 second, predicted percentage (FEV1%), forced expiratory volume in 1 second (FEV1), forced expiratory volume in 1 second The vital capacity percentage (FEV1 / FVC). Results The total effective rate of the observation group was higher than that of the control group (P <0.05). There was no significant difference in FEV1%, FEV1, FEV1 / FVC between the two groups before treatment (P> 0.05) The FEV1%, FEV1, FEV1 / FVC in the observation group were higher than those in the control group (P <0.05). Conclusion Jinshuibao capsule has a significant clinical effect in the treatment of chronic obstructive pulmonary disease in acute exacerbation, and can improve lung function of patients.